Last updated: 2026-09-16 09:04:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Charles River Laboratories International, Inc. (CRL) operates in the SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH sector and is listed on NYSE. The stock is currently priced at $272.74, with a market capitalisation of $13.04B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $144.26 to $303.31. This page covers its latest market performance, valuation, price trends and company information.
$13.04B | |
$272.74 | |
$460.21 | |
$19.92 | |
$272.88 | |
1.00 | |
912.68K | |
-- | |
$303.31 | |
$144.26 | |
-- | |
-- |
Charles River Laboratories International, Inc. (CRL) is trading at $272.74 in pre-market trading as of 2026-09-16 08:06:00, down 0.05% ($0.14) from the previous close of $272.88
Pre-market trading shows how investors are pricing CRL before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, Charles River Laboratories International, Inc. (CRL) moved from $288.50 to $272.74, representing a decline of 5.46% ($15.76).
The stock traded between $267.27 and $291.69 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 879.77 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 80.8%
CRL is currently trading at $272.74, placing it 80.8% of the way from its 52-week low of $144.26 to its 52-week high of $303.31. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provide in vitro (nonanimal) testing products, biologics testing services, and avian vaccine services.
| Industry | SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH |
| Employees | 19700 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of Charles River Laboratories International, Inc. (CRL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.